FHTX

Foghorn Therapeutics Inc. is a clinical-stage, precision therapeutics biotechnology company. The Company is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, it is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is also developing multiple product candidates in oncology. The Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within this system. Its platform enables to produce components of the chromatin regulatory system at scale, thereby allowing to identify these genetic dependencies, understand their mechanism and target their vulnerabilities.

Wall Street analysts forecast FHTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FHTX is 11.00 USD with a low forecast of 9.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Foghorn Therapeutics Inc revenue for the last quarter amounts to 8.15M USD, increased 4.42 % YoY.

Foghorn Therapeutics Inc. EPS for the last quarter amounts to -0.25 USD, decreased -19.35 % YoY.

Foghorn Therapeutics Inc (FHTX) has 112 emplpoyees as of January 10 2026.

Today FHTX has the market capitalization of 291.80M USD.